Gold is 2025’s best performer. UBS sees more upside
WESTMINSTER, CO - TriSalus Life Sciences, Inc. (Nasdaq:TLSI), a medical device and pharmaceutical company with a market capitalization of $204 million and significant revenue growth of 46% over the last twelve months, announced the results of its Annual Meeting of Shareholders held on June 12, 2025. The company reported on the election of directors and the ratification of its independent registered accounting firm based on information from vote tabulator Broadridge Investor Communications.
A total of 26,482,799 shares, or 73.2% of the total outstanding shares as of the April 17, 2025, record date, were present in person or by proxy at the meeting. Two nominees for the board of directors were elected for three-year terms expiring in 2028. Mats Wahlström received 20,002,109 votes for, 501,937 abstentions, and there were 5,978,753 broker non-votes. David J. Matlin garnered 20,005,151 votes for, 498,895 abstentions, and again, 5,978,753 broker non-votes.
Additionally, shareholders ratified the appointment of Grant Thornton, LLP as the company’s independent registered accounting firm for the year 2025. The accounting firm was confirmed with 26,445,528 votes for, 36,277 against, and 994 abstentions.
TriSalus Life Sciences, Inc., headquartered in Westminster, Colorado, operates within the surgical and medical instruments and apparatus sector under the industrial classification code 3841. The company maintains a healthy liquidity position with a current ratio of 2.14, though InvestingPro analysis indicates rapid cash consumption. The company is incorporated in Delaware and ends its fiscal year on December 31. Discover more detailed insights and 7 additional ProTips with an InvestingPro subscription.
This report is based on the company’s SEC filing and is provided for informational purposes only. No endorsement or assessment of the significance of the events reported is implied.
In other recent news, TriSalus Life Sciences reported first-quarter revenues of $9.2 million for 2025, marking a 42% increase year-over-year. This growth was driven by the increased utilization of the company’s TriNav system, which accounted for all the revenue during the quarter, although it slightly missed Cantor Fitzgerald’s projection of $9.5 million but surpassed the FactSet consensus estimate of $9.0 million. Despite a slight contraction in gross margin, which fell by 100 basis points to approximately 84%, the company anticipates improvement in margins over the year. TriSalus successfully raised $22 million in gross proceeds through a private placement, which is expected to support its operational goals moving forward.
The company recently launched its TriNav FLX Infusion System, an advancement in its Pressure-Enabled Drug Delivery technology, which qualifies for reimbursement under two Healthcare Common Procedure Coding System codes. This new product is expected to enhance the company’s growth prospects. Additionally, TriSalus announced a leadership change with the appointment of David B. Patience as the new Chief Financial Officer, effective July 2025. Cantor Fitzgerald maintained its Overweight rating on TriSalus, with a price target of $9.00, reflecting confidence in the company’s future prospects despite the CFO transition.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.